Protocol Ledger

NCT06328608 · Phase II/III · RECRUITING

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Interventional Phase II/III clinical trial protocol NCT06328608 sponsored by Chiesi Farmaceutici S.p.A in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-29 Enrollment: 22 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06328608
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)22 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06328608
Protocol FieldVerified Registry Value
NCT IdentifierNCT06328608
Consolidated Lead SponsorChiesi Farmaceutici S.p.A
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment22 participants (ESTIMATED)
Registered Start Date2025-07-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI